Seeking Alpha

simgold11

simgold11
Send Message
View as an RSS Feed
View simgold11's Comments BY TICKER:
Latest  |  Highest rated
  • Visa slips despite beating headline estimates [View news story]
    Biotechs Celgene & Alexion, both of which I own in addition to Visa, also beat estimates, but have tanked. I believe it has to do with the infamous analyst "whisper" estimates.
    Jul 24, 2014. 07:29 PM | Likes Like |Link to Comment
  • 4 Fairy Tales That Questcor Longs Believe [View article]
    As mentioned ad infinitum, Raven, who is obviously an Andrew Left prodigy, mentions the same old tired arguments from last year, sprinkled in with some new seasoning. Being a VT resident, I can assure all that he isn't the typical UVM student. Mentioning your academic majors/minors as Business, Economics, Finance and Entrepreneurship demonstrates what a well-rounded people person you are! You also mentioned in your last post, you and your buddies have a good laugh when your posts draw a reaction. Must be a blast when a lot of people lose money based on your specious and misleading arguments. Yes - you are definitely following in the footsteps of the inimitable fraudulent Mr. Left.
    Dec 8, 2013. 05:16 PM | 3 Likes Like |Link to Comment
  • Phillips 66 (PSX) files to register a proposed IPO for a master limited partnership, Phillips 66 Partners, to occur in H2 of this year. The number of common units to be offered has not been determined, but the MLP expects to receive gross proceeds of ~$300M. [View news story]
    I don't own PSX shares, but know it has been in IBD50. I invested in Sunoco Logistics (SLX) in IRA 4 months ago directly. It was a spin-off of Sunoco, with a similar arrangement to this, and a K-1. I invested in it without recommendation due to robust dividend, low beta, insider purchases, and very good ratings from IBD and MSN.com services. It has appreciated over 30% in a little over 4 months.
    Mar 31, 2013. 07:11 PM | Likes Like |Link to Comment
  • More on Questcor Pharmaceuticals (QCOR): Q4 beats on all counts as total revenue jumped 113% Y/Y, primarily due to expanded Acthar prescriptions in the treatment of nephrotic syndrome as well as the treatment of MS relapses and infantile spasms. Net sales also benefited from the initiation of commercial activities focused on the use of Acthar in the treatment of rheumatology-related conditions. Despite the overall better numbers, the shares are -6.6% AH. [View news story]
    Without checking, my guess is further manipulation by Andrew Left of
    Citron Research. This short seller has been on a mission to downgrade the stock, and it fits the convicted felon's pattern.
    Feb 27, 2013. 12:50 PM | Likes Like |Link to Comment
  • As S&P 500 Enters Buying Territory, Questcor's Reward Outweighs Risk [View article]
    keiithc71 - I'm glad you brought this up. Citron is a one-man operation, and this individual, Andrew Left, has a long list of crimes and shady dealings to his record, as a Google search will indicate. He charges Questcor with fraud - based on his record, if anybody knows fraud, it's Andrew Left. He is obviously manipulating the market to make a killing, and it appears he has a vendetta against Questcor. It seems likely that after the short positions are covered, he will come back later to force his prediction of single digits to come to fruition. I'm thinking of making a few targeted phone calls - as the OWS movement has pointed out, nobody is more unpopular with the public than unprincipled Wall Street operators.
    Oct 4, 2012. 10:40 PM | 3 Likes Like |Link to Comment
  • Little Risk, Plenty Of Upside For Questcor Around Aetna Policy Update [View article]
    This is an excellent balanced piece of work. I agree with ggppique. There are 2 other factors, which may or may not have an influence. With Obamacare officially law (I can't see the GOP seriously trying to revoke it based on the SCOTUS decision, and the negative impact on their future viability), insurance abuses now are at least more in the public's frame of awareness. Additionally, Citron Research is basically a one-man shop run by Andrew Left, who has a very shady background (see below link). Aided by OWS, no institution is more hated than Wall Street. I don't know how much clout Left and other short-sellers have, but I have gone to several Bernie Sanders fund-raisers, and I know what his reaction would be to the market manipulation practiced by Left, Chanos and other short sellers.

    http://bit.ly/VvgDBu
    Oct 3, 2012. 01:44 PM | Likes Like |Link to Comment
  • Coinstar (CSTR -0.2%) CEO Paul Davis stubs out rumors the company is trying to sell itself, saying execs have "no idea" where the story came from. Despite the denial, shares remain at elevated levels. [View news story]
    After last earnings report, shares were vastly oversold to begin with. Hopefully, this will get the ball rolling.
    Aug 17, 2012. 12:19 PM | Likes Like |Link to Comment
  • Questcor (QCOR -11.5%), which opened today near its all-time high, plunges after Citron Research issues a report (.pdf) questioning the sustainability of Acthar gel sales. Citron points to the decades-old availability of similar generic products, Novartis' launch of a synthetic alternative, and insurance industry pushback. Citron also goes after Questcor's low R&D spending and unexplained marketing expenses. (yesterday) (TheStreetSweeper)  [View news story]
    As mentioned in other stories, Citron Research is a well-known short seller, who is obviously orchestrating a large profit on their part. I think it's morally despicable, if not illegal. This is why individual investors like myself completely lose trust in the market. The same thing happened with GMCR a while back - luckily I got out in time then.

    I am an IT professional, and obviously a QCOR investor - Mitch
    Jul 10, 2012. 02:43 PM | 2 Likes Like |Link to Comment
COMMENTS STATS
8 Comments
8 Likes